Information  X 
Enter a valid email address

Onzima Ventures PLC (ONZ)


Monday 11 July, 2016

Onzima Ventures PLC

Update re Investment

Onzima Ventures PLC

("Onzima" or the "Company")

N4 Pharma announces further patent filings for reformulation of Valsartan and Losartan

Onzima is pleased to announce that N4 Pharma Limited ("N4 Pharma"), its 49%-owned investee company, has filed 17 novel patents for the reformulation of losartan and 12 novel patents for the reformulation of valsartan.

This is in line with its strategy of filing strong broad patents for a range of drugs that it wishes to consider reformulating and are part of the suite of patents that N4 Pharma acquired from OPAL IP.

N4 Pharma CEO Nigel Theobald commented:  "These are the first of a range of other reformulation patents we intend to file for a number of existing generic or soon to be generic drugs in addition to those already filed for Sildenafil.

“We will continue to file strong life cycle management patents for a range of drugs over the coming weeks and months. Our initial formulation focus is still on our work for Sildenafil and we are now working with clinicians and formulators to decide which of these additional new drugs we will start reformulation work on next.

“Sartans are the most recent class of anti-hypertensive agents and are extremely effective at relaxing smooth muscle in the arteries and thereby relieve hypertension. Since sartans are effectively metabolised by the body, the drug level is not effectively maintained in the body overnight which causes increased blood pressure on waking, resulting in potential patient health issues.

“Our reformulation will look to maintain the dose more effectively overnight thereby reducing the nocturnal deficit of the drug and maintain low blood pressure throughout the drug dose, giving a unique clinical position in the sartans market which, in 2015, returned global sales of $11bn".

For further information please contact:       

Onzima Ventures PLC                                                Tel:  +44 (0) 1732 366 561

Gavin Burnell, Luke Cairns

Nominated Adviser

Cairn Financial Advisers LLP                                     Tel:  +44 (0) 20 7148 7900     

Sandy Jamieson, Liam Murray


Peterhouse Corporate Finance Limited                      Tel:  +44 (0) 20 7469 0930 

Guy Miller, Lucy Williams

a d v e r t i s e m e n t